Tak Paul Peter
Chief Executive Officer
Sale 10b5-1
- Shares
- 59,379
- Price
- $10.46
- Value
- $620,891
SEC EDGAR · Forms 3/4/5Updated through Oct 30, 2026•33 filings
CADL
Candel Therapeutics, Inc.
Net sales of $3.2M over the last 3 months
2 sellers account for the net balance. There is no cluster of three distinct buyers within 30 days. We found no CEO/CFO purchases over 12 months.
How to read this signal
Only open-market P purchases and S sales count toward the signal. Vesting, options, taxes and gifts remain in the source data but do not trigger alerts. Rule 10b5-1 trades are shown as informational.
3-month balance
−$3,244,783
0 buyers · 2 sellers
12-month purchases
$2,999,996
1 distinct insiders
12-month sales
$3,550,703
3 distinct insiders
Highlighted alerts
1
6 Rule 10b5-1 trades treated as informational
Buying cluster · 30 days
Fewer than three distinct buyers
CEO/CFO purchases · 12 months
No executive purchases found
Get CADL insider trades by API
The same filtered trades as JSON for your scripts, alerts or AI agent, for 5,500+ US companies — plus sentiment, news, financials and breakout setups. Free · every API · 1,000 requests a month · no card required.
CADL overview: breakout setup, X sentiment and insiders in one page →
Form 4 raw → Raspberry
The value is in what we do not call a signal.
The SEC XML stores every transaction. Raspberry keeps that evidence, reads the footnotes and separates voluntary open-market activity from vesting, option exercises, gifts, tax withholding, stock purchase and dividend reinvestment plans and pre-programmed 10b5-1 trades.
36
Raw transactions
Everything returned by the filing
7
Voluntary view
P/S trades after deterministic checks
29
Administrative noise
Stored, never alerted
10
10b5-1
Shown as informational
SEC ownership XML facts
- Code
- A
- Shares
- 380
- Price
- $8.68
- Footnotes
- 1
This award has been granted in lieu of normal quarterly cash payments. The underlying award quantity is fully vested at time of grant.
Recent transactions
Voluntary purchases and sales; administrative noise stays hidden.
Tak Paul Peter
Chief Executive Officer
Sale 10b5-1
- Shares
- 220,866
- Price
- $11.50
- Value
- $2,539,893
Tyagarajan Seshu
Chief Technology Officer
Sale 10b5-1
- Shares
- 7,000
- Price
- $12.00
- Value
- $84,000
Tyagarajan Seshu
Chief Technology Officer
Sale 10b5-1
- Shares
- 7,000
- Price
- $10.02
- Value
- $70,151
Barone Francesca
Chief Scientific Officer
Sale 10b5-1
- Shares
- 23,447
- Price
- $10.06
- Value
- $235,769
Manning Paul B
Director
PurchaseAlert
- Shares
- 550,458
- Price
- $5.45
- Value
- $2,999,996
Nichols William Garrett
Chief Medical Officer
Sale 10b5-1
- Shares
- 937
- Price
- $6.98
- Value
- $6,540
| Date | Insider | Transaction | Shares | Price | Value | Reading |
|---|---|---|---|---|---|---|
| Sep 11, 2026 | Tak Paul Peter Chief Executive Officer | Sale | 59,379 | $10.46 | $620,891 | |
| Sep 10, 2026 | Tak Paul Peter Chief Executive Officer | Sale | 220,866 | $11.50 | $2,539,893 | |
| Aug 17, 2026 | Tyagarajan Seshu Chief Technology Officer | Sale | 7,000 | $12.00 | $84,000 | |
| Jun 29, 2026 | Tyagarajan Seshu Chief Technology Officer | Sale | 7,000 | $10.02 | $70,151 | |
| Jun 29, 2026 | Barone Francesca Chief Scientific Officer | Sale | 23,447 | $10.06 | $235,769 | |
| Feb 23, 2026 | Manning Paul B Director | Purchase | 550,458 | $5.45 | $2,999,996 | |
| Jul 28, 2025 | Nichols William Garrett Chief Medical Officer | Sale | 937 | $6.98 | $6,540 |
“Alert” means a voluntary, unscheduled transaction according to the filing; it is not an investment recommendation. Official source: SEC EDGAR.